FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
Pfizer declares first-quarter 2024 dividend
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
FDA grants Priority Review to Amgen's tarlatamab application for advanced small cell lung cancer
- Details
- Category: Amgen
![Amgen Amgen](/images/logo/amgen.png)
Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
AstraZeneca to acquire Icosavax
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](/images/logo/astrazeneca.png)
The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV),
Bayer and Salus Optima partner on AI-enabled healthy aging journey
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer and Hurdle launch precision health strategic partnership
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
More Pharma News ...
- Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
- Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
- Bayer and Recursion focus research collaboration on oncology
- Bayer expands global life science incubator network
- Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
- AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions